v3.26.3
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development $ 1,512,898 $ 922,857 $ 4,808,183 $ 3,099,667
General and administrative 1,870,678 1,020,154 5,330,134 3,399,559
Total operating expenses 3,383,576 1,943,011 10,138,317 6,499,226
Loss from operations (3,383,576) (1,943,011) (10,138,317) (6,499,226)
Other income (expense), net:        
Other income (expense), net 68,063 35,224 490,369 94,512
Change in fair value of warrant liability 0 611 0 2,071
Total other income (expense), net 68,063 35,835 490,369 96,583
Net loss (3,315,513) (1,907,176) (9,647,948) (6,402,643)
Deemed dividends 0 (2,769,742) (5,681,616) (5,951,528)
Net loss attributable to common stockholders $ (3,315,513) $ (4,676,918) $ (15,329,564) $ (12,354,171)
Net loss per share, basic $ (5.92) $ (49.51) $ (29.37) $ (273.33)
Net loss per share, diluted $ (5.92) $ (49.51) $ (29.37) $ (273.33)
Weighted-average shares used to compute net loss per share, basic 559,596 94,455 522,028 45,199
Weighted-average shares used to compute net loss per share, diluted 559,596 94,455 522,028 45,199